文献速递免疫规划

磷酸钙纳米颗粒(CaPNP)用于小鼠2009年甲型H1N1流感大流行灭活全病毒疫苗的剂量节省

Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.
PubMed 文献 · Vaccine · 2017-07-14

本研究利用CaPtivate公司的磷酸钙纳米颗粒(CaPNP)佐剂与递送平台,配制2009年甲型H1N1流感大流行灭活全病毒疫苗,在BALB/c小鼠单次肌内注射三种抗原剂量(基于HA含量0.3、1或3μg)后评估免疫原性与保护效果。结果显示,各剂量下CaPNP组血凝抑制、病毒中和及IgG抗体滴度均显著高于无佐剂疫苗,且含CaPNP疫苗以1/3抗原剂量即可提供与无佐剂或铝佐剂疫苗同等的保护。

要点

  • CaPNP佐剂在各抗原剂量下均显著提高血凝抑制、病毒中和及IgG抗体滴度,优于无佐剂疫苗。
  • 含CaPNP疫苗以1/3抗原剂量即可提供与无佐剂或铝佐剂疫苗同等的保护。
  • 作者认为CaPNP是有吸引力的疫苗佐剂与递送系统,但需进一步研究验证其替代现有流感疫苗佐剂的能力。

核心结论

  • CaPNP佐剂可增强2009年甲型H1N1流感大流行灭活全病毒疫苗在小鼠中的免疫原性并实现剂量节省。
  • 作者认为CaPNP是有吸引力的疫苗佐剂与递送系统,应在安全有效剂量节省疫苗开发中发挥重要作用。
  • 作者指出需进一步研究验证CaPNP作为现有流感/大流行流感疫苗佐剂替代品的能力。

研究设计与样本

  • 研究使用CaPtivate公司的磷酸钙纳米颗粒(CaPNP)佐剂与递送平台配制2009年甲型H1N1流感大流行灭活全病毒疫苗。
  • 在BALB/c小鼠中单次肌内注射三种不同抗原剂量(基于HA含量0.3、1或3μg)的疫苗,并与无佐剂或铝佐剂疫苗进行比较。

主要发现

  • 与无佐剂疫苗相比,含CaPNP疫苗在所有剂量水平均引起显著更高的血凝抑制(HAI)、病毒中和(VN)和IgG抗体滴度。
  • 含CaPNP疫苗以1/3抗原剂量即可提供与无佐剂或铝佐剂疫苗同等的保护。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 作者指出需进一步研究验证CaPNP作为现有流感/大流行流感疫苗佐剂替代品的能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The emergence of pandemic influenza strains, particularly the reemergence of the swine-derived influenza A (H1N1) in 2009, is reaffirmation that influenza viruses are very adaptable and influenza remains as a significant global public health treat. As recommended by the World Health Organization (WHO), the use of adjuvants is an attractive approach to improve vaccine efficacy and allow dose-sparing during an influenza emergency. In this study, we utilized CaPtivate Pharmaceutical's proprietary calcium phosphate nanoparticles (CaPNP) vaccine adjuvant and delivery platform to formulate an inactivated whole virus influenza A/CA/04/2009 (H1N1pdm) vaccine as a potential dose-sparing strategy. We evaluated the relative immunogenicity and the efficacy of the formulation in BALB/c mice following single intramuscularly administration of three different doses (0.3, 1, or 3µg based on HA content) of the vaccine in comparison to non-adjuvanted or alum-adjuvant vaccines. We showed that, addition of CaPNP in vaccine elicited significantly higher hemagglutination inhibition (HAI), virus neutralization (VN), and IgG antibody titers, at all dose levels, relative to the non-adjuvanted vaccine. In addition, the vaccine containing CaPNP provided equal protection with 1/3rd of the antigen dose as compared to the non-adjuvanted or alum-adjuvanted vaccines. Our data provided support to earlier studies indicating that CaPNP is an attractive vaccine adjuvant and delivery system and should play an important role in the development of safe and efficacious dose-sparing vaccines. Our findings also warrant further investigation to validate CaPNP's capacity as an alternative adjuvant to the ones currently licensed for influenza/pandemic influenza vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Morçӧl T, Hurst BL, Tarbet EB, et al. Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice. Vaccine. 2017. PMID: 28716554. doi:10.1016/j.vaccine.2017.07.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。